U
Ulrich T. Hopt
Researcher at University of Freiburg
Publications - 349
Citations - 11279
Ulrich T. Hopt is an academic researcher from University of Freiburg. The author has contributed to research in topics: Pancreatitis & Pancreas. The author has an hindex of 50, co-authored 347 publications receiving 10112 citations. Previous affiliations of Ulrich T. Hopt include University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Ulrich F. Wellner,Jörg Schubert,Ulrike Burk,Otto Schmalhofer,Feng Zhu,Annika G Sonntag,Bettina Waldvogel,Corinne Vannier,Douglas S. Darling,Axel zur Hausen,Valerie G. Brunton,Jennifer P. Morton,Owen J. Sansom,Julia Schüler,Marc P. Stemmler,Christoph Herzberger,Ulrich T. Hopt,Tobias Keck,Simone Brabletz,Thomas Brabletz +19 more
TL;DR: It is proposed that ZEB1 links EMT-activation and stemness-maintenance by suppressingstemness-inhibiting microRNAs (miRNAs) and thereby is a promoter of mobile, migrating cancer stem cells.
Journal ArticleDOI
The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer
Hartwig Riediger,Tobias Keck,Ulrich F. Wellner,Axel zur Hausen,Ulrich Adam,Ulrich T. Hopt,Frank Makowiec +6 more
TL;DR: The routine estimation of the LN ratio may be helpful not only for the individual prediction of prognosis but also for the indication of adjuvant therapy and herein related outcome and therapy studies.
Journal ArticleDOI
Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface.
Peter Bronsert,Kathrin Enderle-Ammour,Moritz Bader,Sylvia Timme,M Kuehs,Agnes Csanadi,Gian Kayser,Ilona Kohler,D Bausch,Jens Hoeppner,Ulrich T. Hopt,Tobias Keck,Elmar Stickeler,Bernward Passlick,Oliver Schilling,CP Reiss,Y Vashist,Thomas Brabletz,J. P. Berger,Johannes Lotz,Janine Olesch,Martin Werner,Ulrich F. Wellner +22 more
TL;DR: The relationship between current biological and clinical concepts such as cell migration modes, tumour budding and epithelial-mesenchymal transition (EMT) remains unclear in several aspects, especially for the'real' situation in human cancer as mentioned in this paper.
Journal ArticleDOI
Mutant KRAS -driven cancers depend on PTPN11 /SHP2 phosphatase
Dietrich A. Ruess,Dietrich A. Ruess,Guus J.J.E. Heynen,Katrin J. Ciecielski,Jiaoyu Ai,Alexandra Berninger,Derya Kabacaoglu,Kivanc Görgülü,Zahra Dantes,S Wörmann,Kalliope N. Diakopoulos,Angeliki Faidra Karpathaki,Marlena Kowalska,Ezgi Kaya-Aksoy,Liang Song,Eveline A.N. Zeeuw van der Laan,María P. López-Alberca,Marc Nazaré,Maximilian Reichert,Dieter Saur,Mert Erkan,Ulrich T. Hopt,Bruno Sainz,Walter Birchmeier,Roland M. Schmid,Marina Lesina,Hana Algül +26 more
TL;DR: The data indicate the clinical utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers and provide evidence for a critical dependence of mutant KRAS on SHp2 during carcinogenesis.
Journal ArticleDOI
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
Jens Hoeppner,Florian Lordick,Thomas Brunner,Torben Glatz,Peter Bronsert,N Rothling,Claudia Schmoor,Dietmar Lorenz,Christian Ell,Ulrich T. Hopt,J. Rüdiger Siewert +10 more
TL;DR: The ESOPEC trial compares perioperative chemotherapy according to the FLOT protocol to neoadjuvant chemoradiation according toThe CROSS protocol in multimodal treatment of non-metastasized recectable adenocarcinoma of the esophagus and the gastroesophageal junction to identify the superior protocol with regard to patient survival, treatment morbidity and quality of life.